Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Gains Phase III Drug/Companion Diagnostic In Deal With Endocyte

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck will acquire rights to develop and commercialize Endocyte’s vintafolide, in Phase III development for ovarian cancer, in exchange for $120 million upfront and up to $880 million in milestones.

You may also be interested in...



Merck/Endocyte Mulling Vintafolide’s Future After Failure In Ovarian Cancer

Endocyte is potentially propelled back to a Phase I company after its nearest commercial prospect flops and its collaboration with Merck is expected to disintegrate now that the drug missed PFS in ovarian cancer.

Merck/Endocyte Mulling Vintafolide’s Future After Failure In Ovarian Cancer

Endocyte is potentially propelled back to a Phase I company after its nearest commercial prospect flops and its collaboration with Merck is expected to disintegrate now that the drug missed PFS in ovarian cancer.

Vedolizumab, Empagliflozin And Vintafolide Receive Positive EU Opinions After CHMP Meeting

The three new medicines tackle ulcerative colitis and Crohn’s disease, diabetes and ovarian cancer, respectively, with final approval from the European Commission expected in around two months.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel